Vuity generic
Vuity is a presbyopia treatment drug owned by Abbvie Inc. This drug, containing pilocarpine hydrochloride, obtained its marketing authorization on October 28, 2021, and is available in solution;ophthalmic dosage forms. Vuity has a total of 2 patents.
When will Vuity generic be available?
The generic versions of Vuity are likely to be available after April 24, 2039. This is due to the drug's patents, the last of which expires on that date.
Vuity uses
Vuity is used for the treatment of presbyopia in adults. The active ingredient, pilocarpine hydrochloride, effectively addresses this condition.
Vuity patent expiration
Vuity holds 2 patents, none of which have expired. The last patent is set to expire on April 24, 2039, after which the Vuity generic will likely become available. Below are the details of the patents: